Here are four highlights:
1. Dr. Landis brings more than 30 years of pharmaceutical research and development experience to the position.
2. He will serve on the board’s science committee.
3. Dr. Landis was most recently Bioanalytical Systems’ board chairman.
4. EyePoint is planning the commercial launches of two ophthalmic products in 2019.
“I look forward to guiding the company as it executes on its strategic and commercial corporate goals in support of the transition to a commercial-stage specialty pharmaceutical company with a pipeline of innovative products for ocular diseases,” Dr. Landis said.
More articles on supply chain:
3 ways ASCs can manage physician preferences
ASC supply chain tip of the day: Collaborate with sales reps
Inventory variability can jeopardize finances — Here’s how you can minimize it
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.